📊 FEED Key Takeaways
Is ENvue Medical, Inc. (FEED) a Good Investment?
ENvue Medical is a pre-revenue/near-revenue stage medical device company with severe financial distress, burning significant cash while generating minimal revenue of just $2.2M despite operating expenses exceeding $10M. The company lacks profitability with negative operating margins of -360% and negative free cash flow of -$6.7M, with only $7.0M in cash and current liabilities exceeding current assets, creating acute solvency risk.
ENvue Medical shows modest top-line growth, but the business remains fundamentally weak with very low gross margin, extremely negative operating leverage, and free cash flow burn that far exceeds revenue. The balance sheet is not heavily levered, but sub-1.0 liquidity ratios and ongoing operating losses suggest funding risk and poor growth quality unless margins and cash burn improve materially.
Why Buy ENvue Medical, Inc. Stock? FEED Key Strengths
- Strong equity base of $42.5M relative to liabilities of $11.9M provides debt cushion
- Low debt-to-equity ratio of 0.03x indicates minimal financial leverage risk
- Revenue growth of 12% YoY shows early commercialization traction despite small absolute base
- Revenue grew 12.0% year over year, indicating some commercial traction
- Low debt burden with debt/equity of 0.03x limits financial leverage risk
- Positive equity base of $42.46M provides some balance sheet support
FEED Stock Risks: ENvue Medical, Inc. Investment Risks
- Critical liquidity crisis with current ratio of 0.86x and quick ratio of 0.67x; current liabilities exceed current assets
- Massive cash burn of -$6.7M operating cash flow against only $7.0M cash reserves; runway of approximately 12 months at current burn rate
- Operating losses of -$8.1M on revenue of only $2.2M indicate business model not yet viable; gross margin of 23.3% insufficient to cover operating expenses
- Negative free cash flow of -$6.7M with FCF margin of -300% demonstrates inability to self-fund operations
- Diluted EPS of -$6.69 shows severe per-share value destruction despite 41% YoY improvement
- Operating margin of -360.3% and net margin of -238.0% show the business model is not close to self-sustaining
- Negative operating cash flow of $6.70M and free cash flow margin of -300.4% indicate severe cash burn
- Current ratio of 0.86x and quick ratio of 0.67x point to near-term liquidity pressure
Key Metrics to Watch
- Monthly/quarterly revenue growth rate and path to profitability timeline
- Cash burn rate and remaining cash runway with detailed monthly burn analysis
- Gross margin sustainability and whether it can expand to support operating expenses
- Operating expense trajectory and plans for achieving operating breakeven
- Financing activities and likelihood/terms of future capital raises
- Gross margin trend and whether revenue growth is translating into operating leverage
- Cash burn relative to cash balance, especially operating cash flow and current ratio
ENvue Medical, Inc. (FEED) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
FEED Profit Margin, ROE & Profitability Analysis
FEED vs Healthcare Sector: How ENvue Medical, Inc. Compares
How ENvue Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENvue Medical, Inc. Stock Overvalued? FEED Valuation Analysis 2026
Based on fundamental analysis, ENvue Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENvue Medical, Inc. Balance Sheet: FEED Debt, Cash & Liquidity
FEED Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ENvue Medical, Inc.'s revenue has grown significantly by 51% over the 5-year period, indicating strong business expansion. The most recent EPS of $-137.30 indicates the company is currently unprofitable.
FEED Revenue Growth, EPS Growth & YoY Performance
FEED Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $376.0K | $510.0K | $-0.91 |
| Q2 2025 | $494.0K | -$688.0K | $-1.03 |
| Q1 2025 | $921.0K | -$588.0K | $2.38 |
| Q3 2024 | $376.0K | -$727.0K | $-0.36 |
| Q2 2024 | $294.0K | -$688.0K | $-0.25 |
| Q1 2024 | $354.0K | -$588.0K | $-0.23 |
| Q3 2023 | $97.0K | $500.0K | $-0.42 |
| Q2 2023 | $294.0K | $500.0K | $-0.65 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENvue Medical, Inc. Dividends, Buybacks & Capital Allocation
FEED SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ENvue Medical, Inc. (CIK: 0001326706)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FEED
What is the AI rating for FEED?
ENvue Medical, Inc. (FEED) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FEED's key strengths?
Claude: Strong equity base of $42.5M relative to liabilities of $11.9M provides debt cushion. Low debt-to-equity ratio of 0.03x indicates minimal financial leverage risk. ChatGPT: Revenue grew 12.0% year over year, indicating some commercial traction. Low debt burden with debt/equity of 0.03x limits financial leverage risk.
What are the risks of investing in FEED?
Claude: Critical liquidity crisis with current ratio of 0.86x and quick ratio of 0.67x; current liabilities exceed current assets. Massive cash burn of -$6.7M operating cash flow against only $7.0M cash reserves; runway of approximately 12 months at current burn rate. ChatGPT: Operating margin of -360.3% and net margin of -238.0% show the business model is not close to self-sustaining. Negative operating cash flow of $6.70M and free cash flow margin of -300.4% indicate severe cash burn.
What is FEED's revenue and growth?
ENvue Medical, Inc. reported revenue of $2.2M.
Does FEED pay dividends?
ENvue Medical, Inc. does not currently pay dividends.
Where can I find FEED SEC filings?
Official SEC filings for ENvue Medical, Inc. (CIK: 0001326706) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FEED's EPS?
ENvue Medical, Inc. has a diluted EPS of $-6.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FEED a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ENvue Medical, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FEED stock overvalued or undervalued?
Valuation metrics for FEED: ROE of -12.6% (sector avg: 15%), net margin of -238.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FEED stock in 2026?
Our dual AI analysis gives ENvue Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FEED's free cash flow?
ENvue Medical, Inc.'s operating cash flow is $-6.7M, with capital expenditures of $37.0K. FCF margin is -300.4%.
How does FEED compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -238.0% (avg: 12%), ROE -12.6% (avg: 15%), current ratio 0.86 (avg: 2).